Ash1l degraders and methods of treatment therewith
US-2024366774-A1 · Nov 7, 2024 · US
Targeting the neuromuscular junction for treatment
US8961981B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8961981-B2 |
| Application number | US-201213527142-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2012 |
| Priority date | Jun 20, 2011 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a neuromuscular junction targeting peptide coupled to a therapeutic agent, wherein the neuromuscular junction targeting peptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9 and wherein the therapeutic agent is selected from the group consisting of a complement inhibitor, an acetylcholinesterase inhibitor, and a trophic agent. 2. The composition of claim 1 , wh…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8961981B2 cover?
- Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neur…
- Who is the assignee on this patent?
- Kaminski Henry, Kusner Linda, Satija Namita, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/64. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).